Vivex Biologics completes enrollment in Phase II trial for back pain therapy Data from the pivotal VIA Disc NP trial are anticipated in early 2026, while a second trial is already in progress, with results expected in mid-2027.

Vivex Biologics has completed enrollment in its ASCEND trial testing VIA Disc NP, a minimally invasive therapy for degenerative disc disease. Results expected Q1 2026.

#News #ClinicalTrial #BackPainRelief #DegenerativeDiscDisease #SpineHealth #VIVEX #VIA DiscNP #PainManagement